Background Drug-induced interstitial lung disease (DI-ILD) encompasses a heterogeneous spectrum of potentially severe pulmonary toxicities associated with various pharmacological agents. Diagnosis is often delayed due to nonspecific symptoms and imaging findings that can mimic other ILDs or infections, particularly in patients receiving oncologic or immunomodulatory therapies. Novel approaches are needed to improve early recognition and management. Methods We conducted a non-systematic, narrative literature review across major biomedical databases up to June 2025, aimed at describing current and emerging applications of artificial intelligence (AI) and radiomics in the early diagnosis, risk stratification, and personalised management of DI-ILD. Results Radiomics applied to CT and PET/CT enables extraction of high-dimensional quantitative features capturing subclinical alterations undetectable by visual assessment. In DI-ILD - particularly immune checkpoint inhibitor-related pneumonitis - radiomic models show potential diagnostic utility in distinguishing overlapping imaging patterns and predicting fibrotic progression. Integration with clinical, radiological, and pharmacogenomic data has improved model performance in several studies. Additionally, AI approaches, including convolutional neural networks and ensemble learning methods, demonstrate promise in enhancing pattern recognition and risk stratification. Conclusions Radiomics and AI are emerging complementary tools in multidisciplinary management of DI-ILD, offering objective imaging biomarkers and facilitating multimodal data integration to improve diagnostic precision and personalised therapeutic decisions. Nonetheless, reproducibility remains limited by variability in imaging protocols and lack of large-scale prospective multicentre validation. Clinical implementation requires standardised protocols to ensure consistency and reliability. The development of transparent, interpretable models seamlessly integrated into healthcare workflows is essential to fully leverage their real-world potential in proactive patient care.

Artificial intelligence and radiomics in drug-induced interstitial lung disease / Marchi, Guido; Claudio Fanni, Salvatore; Mercier, Mattia; Cefalo, Jacopo; Salerni, Carmine; Ferioli, Martina; Candoli, Piero; Romei, Chiara; Gori, Leonardo; Cucchiara, Federico; Cenerini, Giovanni; Guglielmi, Giacomo; Pistelli, Francesco; Carrozzi, Laura; Mondoni, Michele. - In: ERJ OPEN RESEARCH. - ISSN 2312-0541. - (2025). [10.1183/23120541.01150-2025]

Artificial intelligence and radiomics in drug-induced interstitial lung disease

Mattia Mercier
Methodology
;
Francesco Pistelli;
2025

Abstract

Background Drug-induced interstitial lung disease (DI-ILD) encompasses a heterogeneous spectrum of potentially severe pulmonary toxicities associated with various pharmacological agents. Diagnosis is often delayed due to nonspecific symptoms and imaging findings that can mimic other ILDs or infections, particularly in patients receiving oncologic or immunomodulatory therapies. Novel approaches are needed to improve early recognition and management. Methods We conducted a non-systematic, narrative literature review across major biomedical databases up to June 2025, aimed at describing current and emerging applications of artificial intelligence (AI) and radiomics in the early diagnosis, risk stratification, and personalised management of DI-ILD. Results Radiomics applied to CT and PET/CT enables extraction of high-dimensional quantitative features capturing subclinical alterations undetectable by visual assessment. In DI-ILD - particularly immune checkpoint inhibitor-related pneumonitis - radiomic models show potential diagnostic utility in distinguishing overlapping imaging patterns and predicting fibrotic progression. Integration with clinical, radiological, and pharmacogenomic data has improved model performance in several studies. Additionally, AI approaches, including convolutional neural networks and ensemble learning methods, demonstrate promise in enhancing pattern recognition and risk stratification. Conclusions Radiomics and AI are emerging complementary tools in multidisciplinary management of DI-ILD, offering objective imaging biomarkers and facilitating multimodal data integration to improve diagnostic precision and personalised therapeutic decisions. Nonetheless, reproducibility remains limited by variability in imaging protocols and lack of large-scale prospective multicentre validation. Clinical implementation requires standardised protocols to ensure consistency and reliability. The development of transparent, interpretable models seamlessly integrated into healthcare workflows is essential to fully leverage their real-world potential in proactive patient care.
2025
AI, radiomics
01 Pubblicazione su rivista::01a Articolo in rivista
Artificial intelligence and radiomics in drug-induced interstitial lung disease / Marchi, Guido; Claudio Fanni, Salvatore; Mercier, Mattia; Cefalo, Jacopo; Salerni, Carmine; Ferioli, Martina; Candoli, Piero; Romei, Chiara; Gori, Leonardo; Cucchiara, Federico; Cenerini, Giovanni; Guglielmi, Giacomo; Pistelli, Francesco; Carrozzi, Laura; Mondoni, Michele. - In: ERJ OPEN RESEARCH. - ISSN 2312-0541. - (2025). [10.1183/23120541.01150-2025]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1762417
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact